内分泌代谢系统疾病与继发性骨质疏松症的研究新进展

doi:10.12114/j.issn.1007-9572.2024.0696

中国全科医学 ›› 2025, Vol. 28 ›› Issue (17): 2082-2091.DOI: 10.12114/j.issn.1007-9572.2024.0696

• 专题笔谈·继发性骨质疏松症 • 上一篇下一篇

内分泌代谢系统疾病与继发性骨质疏松症的研究新进展

陈钡钡¹^,², 李佳¹^,²^,³^,^*(), 谭文彬²^,³

¹510006　广东省广州市，广东药科大学研究生院
²510010　广东省广州市，中国人民解放军南部战区总医院内分泌科
³510515　广东省广州市，南方医科大学第一临床医学院

收稿日期:2025-01-10 修回日期:2025-03-10 出版日期:2025-06-15 发布日期:2025-04-22
通讯作者: 李佳
作者贡献：
陈钡钡负责论文的构思与起草；李佳指导论文的构思、修订和质量控制，对论文整体负责；谭文彬负责论文修订。
基金资助:
国家重点研发计划(2021YFC2501701); 广东省中央引导地方科技发展专项基金(KTP20190249)

Progress in the Research of Endocrine and Metabolic System Diseases and Secondary Osteoporosis

CHEN Beibei¹^,², LI Jia¹^,²^,³^,^*(), TAN Wenbin²^,³

¹Graduate School of Guangdong Pharmaceutical University, Guangzhou 510006, China
²Department of Endocrinology, General Hospital of Southern Theater Command of the People's Liberation Army, Guangzhou 510010, China
³The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China

Received:2025-01-10 Revised:2025-03-10 Published:2025-06-15 Online:2025-04-22
Contact: LI Jia

分享到

摘要/Abstract

摘要： 继发性骨质疏松症（SOP）与各种内分泌代谢疾病有关。骨的生长发育离不开内分泌系统的调节，甲状腺功能亢进症、性腺功能减退症、高泌乳素血症等内分泌代谢疾病可打破骨吸收和骨形成的平衡，增加OP及骨折风险。为有效管理内分泌代谢病所致的SOP，有必要深入探讨其发病机制、诊断方法及治疗方案。本文从SOP在不同内分泌代谢疾病群体中的流行病学特征、激素失衡及细胞信号通路异常等发病机制、骨代谢指标与骨密度等骨损害特点，以及诊疗进展4个方面进行论述，为内分泌代谢系统疾病患者防治SOP提供参考。

关键词: 继发性骨质疏松症, 骨质疏松, 甲状腺功能亢进症, 高泌乳素血症, 性腺功能减退症, 发病机制, 治疗

Abstract:

Secondary osteoporosis (OP) is mostly related to endocrine and metabolic diseases. The growth and development of bone is inseparable from the regulation of the endocrine system. Endocrine and metabolic diseases such as hyperthyroidism, hypogonadism, and hyperprolactinemia can break the balance between bone resorption and bone formation, and increase the risk of osteoporosis and fracture. In order to effectively manage secondary OP caused by endocrine and metabolic diseases, it is particularly important to explore its mechanism, diagnostic methods and treatment options. This article reviews the epidemiological characteristics of secondary osteoporosis in different groups of endocrine and metabolic diseases, the pathogenesis of hormone imbalance and cell signaling pathway abnormalities, the characteristics of bone damage such as bone metabolism indicators and bone mineral density, and the progress in the diagnosis and treatment of secondary osteoporosis, so as to provide reference for the prevention and treatment of secondary osteoporosis in patients with endocrine and metabolic diseases.

Key words: Secondary osteoporosis, Osteoporosis, Hyperthyroidism, Hyperprolactinemia, Hypogonadism, Pathogenesis, Treatment

陈钡钡,李佳,谭文彬. 内分泌代谢系统疾病与继发性骨质疏松症的研究新进展[J]. 中国全科医学, 2025, 28(17): 2082-2091. DOI: 10.12114/j.issn.1007-9572.2024.0696.
CHEN Beibei,LI Jia,TAN Wenbin. Progress in the Research of Endocrine and Metabolic System Diseases and Secondary Osteoporosis[J]. Chinese General Practice, 2025, 28(17): 2082-2091. DOI: 10.12114/j.issn.1007-9572.2024.0696.

参考文献 99

[1]	王姿，齐艳喆，潘荣斌，等. 中医药调控内分泌系统治疗骨质疏松症研究概况[J]. 中国实验方剂学杂志，2023，29(20)：221-229. DOI：10.13422/j.cnki.syfjx.20230939.
[2]	谭文彬，李佳，刘明玉，等. 糖尿病及降糖药物对骨代谢及骨折影响的相关研究进展[J]. 解放军医学院学报，2024，45(1)：44-48. DOI：10.12435/j.issn.2095-5227.2023.151.
[3]	BILEZIKIAN J P, KHAN A A, SILVERBERG S J, et al. Evaluation and management of primary hyperparathyroidism：summary statement and guidelines from the fifth international workshop[J]. J Bone Miner Res，2022，37(11)：2293-2314. DOI：10.1002/jbmr.4677.
[4]	李巧，姚军，吴红花，等. 库欣综合征合并骨质疏松症患者的临床特点及骨密度相关因素分析[J]. 中国骨质疏松杂志，2018，24(8)：1034-1039，1048. DOI：10.3969/j.issn.1006-7108.2018.08.011.
[5]	SUN Q Y, SUN W W, YE H Y, et al. The efficacy of bisphosphonates for osteoporosis in young Cushing's disease patients with biochemical remission：a retrospective cohort study[J]. Front Endocrinol，2024，15：1412046. DOI：10.3389/fendo.2024.1412046.
[6]	POLI A, BRUSCHI F, CESANA B, et al. Plasma low-density lipoprotein cholesterol and bone mass densitometry in postmenopausal women[J]. Obstet Gynecol，2003，102(5 Pt 1)：922-926. DOI：10.1016/j.obstetgynecol.2003.07.004.
[7]	覃博金，苏海玲，罗含茵，等. 壮族骨折患者的血脂水平与骨质疏松性骨折的关系[J]. 广西医学，2022，44(13)：1483-1486. DOI：10.11675/j.issn.0253-4304.2022.13.10.
[8]	ANAGNOSTIS P, FLORENTIN M, LIVADAS S, et al. Bone health in patients with dyslipidemias：an underestimated aspect[J]. Int J Mol Sci，2022，23(3)：1639. DOI：10.3390/ijms23031639.
[9]	LI G H, CHEUNG C L, AU P C, et al. Positive effects of low LDL-C and statins on bone mineral density：an integrated epidemiological observation analysis and Mendelian randomization study[J]. Int J Epidemiol，2020，49(4)：1221-1235. DOI：10.1093/ije/dyz145.
[10]	LIN X, PENG C, GREENBAUM J, et al. Identifying potentially common genes between dyslipidemia and osteoporosis using novel analytical approaches[J]. Mol Genet Genomics，2018，293(3)：711-723. DOI：10.1007/s00438-017-1414-1.
[11]	DENNISON E M, SYDDALL H E, AIHIE SAYER A, et al. Lipid profile，obesity and bone mineral density：the Hertfordshire Cohort Study[J]. QJM，2007，100(5)：297-303. DOI：10.1093/qjmed/hcm023.
[12]	XIE R J, HUANG X J, LIU Q L, et al. Positive association between high-density lipoprotein cholesterol and bone mineral density in U.S. adults：the NHANES 2011-2018[J]. J Orthop Surg Res，2022，17(1)：92. DOI：10.1186/s13018-022-02986-w.
[13]	SUN Y B, QI X, WANG X, et al. Association between high-density lipoprotein cholesterol and lumbar bone mineral density in Chinese：a large cross-sectional study[J]. Lipids Health Dis，2024，23(1)：27. DOI：10.1186/s12944-024-02023-1.
[14]	YIN W Z, LI Z R, ZHANG W Z. Modulation of bone and marrow niche by cholesterol[J]. Nutrients，2019，11(6)：1394. DOI：10.3390/nu11061394.
[15]	徐晓丽，孙迎，丁燕，等. 胆固醇对骨代谢影响的研究进展[J]. 中国骨质疏松杂志，2021，27(6)：895-900. DOI：10.3969/j.issn.1006-7108.2021.06.022.
[16]	WANG J Z, LI S S, PU H Y, et al. The association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and the risk of osteoporosis among U.S. adults：analysis of NHANES data[J]. Lipids Health Dis，2024，23(1)：161. DOI：10.1186/s12944-024-02152-7.
[17]	ZHENG M, WAN Y N, LIU G W, et al. Differences in the prevalence and risk factors of osteoporosis in Chinese urban and rural regions：a cross-sectional study[J]. BMC Musculoskelet Disord，2023，24(1)：46. DOI：10.1186/s12891-023-06147-w.
[18]	SONG Y F, LIU J J, ZHAO K, et al. Cholesterol-induced toxicity：an integrated view of the role of cholesterol in multiple diseases[J]. Cell Metab，2021，33(10)：1911-1925. DOI：10.1016/j.cmet.2021.09.001.
[19]	PELTON K, KRIEDER J, JOINER D, et al. Hypercholesterolemia promotes an osteoporotic phenotype[J]. Am J Pathol，2012，181(3)：928-936. DOI：10.1016/j.ajpath.2012.05.034.
[20]	ZHOU Y M, DENG T, ZHANG H Q, et al. Hypercholesterolaemia increases the risk of high-turnover osteoporosis in men[J]. Mol Med Rep，2019，19(6)：4603-4612. DOI：10.3892/mmr.2019.10131.
[21]	XIE R J, HUANG X J, ZHANG Y, et al. High low-density lipoprotein cholesterol levels are associated with osteoporosis among adults 20-59 years of age[J]. Int J Gen Med，2022，15：2261-2270. DOI：10.2147/IJGM.S353531.
[22]	HONG W, WEI Z Y, QIU Z H, et al. Atorvastatin promotes bone formation in aged apoE-/- mice through the Sirt1-Runx2 axis[J]. J Orthop Surg Res，2020，15(1)：303. DOI：10.1186/s13018-020-01841-0.
[23]	XIONG Z C, YI P, TANG X S, et al. Meta-analysis of the efficacy and safety of alendronate combined with atorvastatin in the treatment of osteoporosis in diabetes mellitus[J]. Biomed Res Int，2022，2022：6747469. DOI：10.1155/2022/6747469.
[24]	ZHU J X, ZHANG C G, JIA J L, et al. Osteogenic effects in a rat osteoporosis model and femur defect model by simvastatin microcrystals[J]. Ann N Y Acad Sci，2021，1487(1)：31-42. DOI：10.1111/nyas.14513.
[25]	PAPAGEORGIOU M, MERMINOD F, FERRARI S, et al. Associations of calcium intake and calcium from various sources with blood lipids in a population of older women and men with high calcium intake[J]. Nutrients，2022，14(6)：1314. DOI：10.3390/nu14061314.
[26]	AL REFAIE A, BALDASSINI L, MONDILLO C, et al. Vitamin D and dyslipidemia：is there really a link? A narrative review[J]. Nutrients，2024，16(8)：1144. DOI：10.3390/nu16081144.
[27]	MOHAMED R H, TAREK M, HAMAM G G, et al. Zoledronic acid prevents the hepatic changes associated with high fat diet in rats；the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis[J]. Eur J Pharmacol，2019，858：172469. DOI：10.1016/j.ejphar.2019.172469.
[28]	ALOMAR S A, GĂMAN M A, PRABAHAR K, et al. The effect of tamoxifen on the lipid profile in women：a systematic review and meta-analysis of randomized controlled trials[J]. Exp Gerontol，2022，159：111680. DOI：10.1016/j.exger.2021.111680.
[29]	DELITALA A P, SCUTERI A, DORIA C. Thyroid hormone diseases and osteoporosis[J]. J Clin Med，2020，9(4)：1034. DOI：10.3390/jcm9041034.
[30]	LEE S Y, PEARCE E N. Hyperthyroidism：a review[J]. JAMA，2023，330(15)：1472-1483. DOI：10.1001/jama.2023.19052.
[31]	KIM S M, RYU V, MIYASHITA S, et al. Thyrotropin，hyperthyroidism，and bone mass[J]. J Clin Endocrinol Metab，2021，106(12)：e4809-4821. DOI：10.1210/clinem/dgab548.
[32]	APOSTU D, LUCACIU O, OLTEAN-DAN D, et al. The influence of thyroid pathology on osteoporosis and fracture risk：a review[J]. Diagnostics，2020，10(3)：149. DOI：10.3390/diagnostics10030149.
[33]	BRANSTETTER R M 4th, ISLAM R K, TOUPS C A, et al. Mechanisms and treatment options for hyperthyroid-induced osteoporosis：a narrative review[J]. Cureus，2023，15(11)：e48798. DOI：10.7759/cureus.48798.
[34]	WÖLFEL E M, LADEMANN F, HEMMATIAN H, et al. Reduced bone mass and increased osteocyte tartrate-resistant acid phosphatase（TRAP）activity，but not low mineralized matrix around osteocyte lacunae，are restored after recovery from exogenous hyperthyroidism in male mice[J]. J Bone Miner Res，2023，38(1)：131-143. DOI：10.1002/jbmr.4736.
[35]	王苹. 骨转换标志物对Graves病患者骨量异常的识别作用[J]. 中国地方病防治，2022，37(4)：335-337.
[36]	LIN S Y, LIN C L, CHEN H T, et al. Risk of osteoporosis in thyroid cancer patients using levothyroxine：a population-based study[J]. Curr Med Res Opin，2018，34(5)：805-812. DOI：10.1080/03007995.2017.1378174.
[37]	中华医学会内分泌学分会，中华医学会外科学分会甲状腺及代谢外科学组，中国抗癌协会头颈肿瘤专业委员会，等. 甲状腺结节和分化型甲状腺癌诊治指南（第二版）[J]. 国际内分泌代谢杂志，2023，43(2)：149-194. DOI：10.3760/cma.j.cn311282-20221023-00589-1.
[38]	MIRZA F, CANALIS E. Management of endocrine disease：secondary osteoporosis：pathophysiology and management[J]. Eur J Endocrinol，2015，173(3)：R131-151. DOI：10.1530/EJE-15-0118.
[39]	PARK S Y, KIM J, CHUNG H Y. Denosumab-induced hypocalcemia in a patient with hyperthyroidism：a case report[J]. Osteoporos Int，2022，33(1)：305-308. DOI：10.1007/s00198-021-06059-2.
[40]	QI W H, WANG D, HONG Y H, et al. Investigating the causal relationship between thyroid dysfunction diseases and osteoporosis：a two-sample Mendelian randomization analysis[J]. Sci Rep，2024，14(1)：12784. DOI：10.1038/s41598-024-62854-x.
[41]	STEPHANUS A D, RAMOS S C L, SEGUTI V F, et al. Subclinical hypothyroidism is not associated with femoral osteoporosis in individuals aged 50 years or older[J]. J Clin Densitom，2023，26(2)：101362. DOI：10.1016/j.jocd.2023.03.001.
[42]	LEE K, LIM S, PARK H, et al. Subclinical thyroid dysfunction，bone mineral density，and osteoporosis in a middle-aged Korean population[J]. Osteoporos Int，2020，31(3)：547-555. DOI：10.1007/s00198-019-05205-1.
[43]	VESTERGAARD P, MOSEKILDE L. Fractures in patients with hyperthyroidism and hypothyroidism：a nationwide follow-up study in 16，249 patients[J]. Thyroid，2002，12(5)：411-419. DOI：10.1089/105072502760043503.
[44]	HUGHES K, EASTMAN C. Thyroid disease：Long-term management of hyperthyroidism and hypothyroidism[J]. Aust J Gen Pract，2021，50(1/2)：36-42. DOI：10.31128/AJGP-09-20-5653.
[45]	VINTHER C J, POULSEN L H, NICOLAISEN P, et al. Do bone turnover markers reflect changes in bone microarchitecture during treatment of patients with thyroid dysfunction?[J]. J Endocrinol Invest，2023，46(2)：345-358. DOI：10.1007/s40618-022-01907-2.
[46]	SZULC P. Biochemical bone turnover markers in hormonal disorders in adults：a narrative review[J]. J Endocrinol Invest，2020，43(10)：1409-1427. DOI：10.1007/s40618-020-01269-7.
[47]	ALOTAIBE H F, ALOLAIWI L A, ALMUTAIRI A, et al. Association between levothyroxine replacement therapy and osteoporosis in Riyadh，Saudi Arabia：a matched case-control study[J]. Pharmazie，2022，77(10)：295-298. DOI：10.1691/ph.2022.2436.
[48]	EFFRAIMIDIS G, WATT T, FELDT-RASMUSSEN U. Levothyroxine therapy in elderly patients with hypothyroidism[J]. Front Endocrinol，2021，12：641560. DOI：10.3389/fendo.2021.641560.
[49]	PAOLETTA M, MORETTI A, LIGUORI S, et al. Transient osteoporosis of the hip and subclinical hypothyroidism：an unusual dangerous duet? Case report and pathogenetic hypothesis[J]. BMC Musculoskelet Disord，2020，21(1)：543. DOI：10.1186/s12891-020-03574-x.
[50]	MARINA D, RASMUSSEN Å K, BUCH-LARSEN K, et al. Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer：a systematic review[J]. Cancer Med，2023，12(2)：967-982. DOI：10.1002/cam4.4949.
[51]	PETRAMALA L, ZINNAMOSCA L, SETTEVENDEMMIE A, et al. Bone and mineral metabolism in patients with primary aldosteronism[J]. Int J Endocrinol，2014，2014：836529. DOI：10.1155/2014/836529.
[52]	SHI S M, LU C Y, TIAN H M, et al. Primary aldosteronism and bone metabolism：a systematic review and meta-analysis[J]. Front Endocrinol，2020，11：574151. DOI：10.3389/fendo.2020.574151.
[53]	TRANDAFIR A I, GHEORGHE A M, SIMA O C, et al. Cross-disciplinary approach of adrenal tumors：insights into primary aldosteronism-related mineral metabolism status and osteoporotic fracture risk[J]. Int J Mol Sci，2023，24(24)：17338. DOI：10.3390/ijms242417338.
[54]	WANG A N, WANG Y H, LIU H Z, et al. Bone and mineral metabolism in patients with primary aldosteronism：a systematic review and meta-analysis[J]. Front Endocrinol，2022，13：1027841. DOI：10.3389/fendo.2022.1027841.
[55]	SONG S W, CAI X T, HU J L, et al. Effectiveness of spironolactone in reducing osteoporosis and future fracture risk in middle-aged and elderly hypertensive patients[J].Des Dev Ther，2024，18：2215-2225. DOI：10.2147/DDDT.S466904.
[56]	KIM B J, KWAK M K, AHN S H, et al. Lower trabecular bone score in patients with primary aldosteronism：human skeletal deterioration by aldosterone excess[J]. J Clin Endocrinol Metab，2018，103(2)：615-621. DOI：10.1210/jc.2017-02043.
[57]	张琪. 盐皮质激素受体过度活化在糖皮质激素诱导的骨质疏松中的作用研究[D]. 成都：四川大学，2021.
[58]	中华医学会骨质疏松和骨矿盐疾病分会. 男性骨质疏松症诊疗指南[J]. 中华骨质疏松和骨矿盐疾病杂志，2020，13(5)：381-395.
[59]	SHIGEHARA K, IZUMI K, KADONO Y, et al. Testosterone and bone health in men：a narrative review[J]. J Clin Med，2021，10(3)：530. DOI：10.3390/jcm10030530.
[60]	GRANDE G, GRAZIANI A, DI MAMBRO A, et al. Osteoporosis and bone metabolism in patients with Klinefelter syndrome[J]. Endocr Connect，2023，12(8)：e230058. DOI：10.1530/EC-23-0058.
[61]	KETCHEM J M, BOWMAN E J, ISALES C M. Male sex hormones，aging，and inflammation[J]. Biogerontology，2023，24(1)：1-25. DOI：10.1007/s10522-022-10002-1.
[62]	BANDEIRA L, SILVA B C, BILEZIKIAN J P. Male osteoporosis[J]. Arch Endocrinol Metab，2022，66(5)：739-747. DOI：10.20945/2359-3997000000563.
[63]	COLLELUORI G, AGUIRRE L, NAPOLI N, et al. Testosterone therapy effects on bone mass and turnover in hypogonadal men with type 2 diabetes[J]. J Clin Endocrinol Metab，2021，106(8)：e3058-e3068. DOI：10.1210/clinem/dgab181.
[64]	GRIGORYAN S, CLINES G A. Hormonal control of bone architecture throughout the lifespan：implications for fracture prediction and prevention[J]. Endocr Pract，2024，30(7)：687-694. DOI：10.1016/j.eprac.2024.04.006.
[65]	SZULC P. Role of sex steroids hormones in the regulation of bone metabolism in men：Evidence from clinical studies[J]. Best Pract Res Clin Endocrinol Metab，2022，36(2)：101624. DOI：10.1016/j.beem.2022.101624.
[66]	SAKR H F, AMMAR B, ALKHARUSI A, et al. Resveratrol modulates bone mineral density and bone mineral content in A rat model of male hypogonadism[J]. Chin J Integr Med，2023，29(2)：146-154. DOI：10.1007/s11655-022-2895-2.
[67]	JOHNSTON C B, DAGAR M. Osteoporosis in older adults[J]. Med Clin North Am，2020，104(5)：873-884. DOI：10.1016/j.mcna.2020.06.004.
[68]	LEE M J, RYU H K, AN S Y, et al. Testosterone replacement and bone mineral density in male pituitary tumor patients[J]. Endocrinol Metab，2014，29(1)：48-53. DOI：10.3803/EnM.2014.29.1.48.
[69]	CORONA G, VENA W, PIZZOCARO A, et al. Testosterone supplementation and bone parameters：a systematic review and meta-analysis study[J]. J Endocrinol Invest，2022，45(5)：911-926. DOI：10.1007/s40618-021-01702-5.
[70]	ROZENBERG S, BRUYÈRE O, BERGMANN P, et al. How to manage osteoporosis before the age of 50[J]. Maturitas，2020，138：14-25. DOI：10.1016/j.maturitas.2020.05.004.
[71]	YOKOMOTO-UMAKOSHI M, UMAKOSHI H, TSUIKI M, et al. Paraganglioma as a risk factor for bone metastasis[J]. Endocr J，2018，65(3)：253-260. DOI：10.1507/endocrj.EJ17-0368.
[72]	FADIGA L, SARAIVA J, PAIVA I, et al. Thoracic spine metastasis presenting 18 years after complete resection of a phaeochromocytoma[J]. BMJ Case Rep，2019，12(8)：e229621. DOI：10.1136/bcr-2019-229621.
[73]	KHATIWADA S, AGARWAL S, KANDASAMY D, et al. Prevalence and predictors of osteoporosis/BMD below expected range for age in pheochromocytoma/paraganglioma and BMD，TBS change post-operatively：a prospective cohort study[J]. Indian J Endocrinol Metab，2023，27(1)：87-90. DOI：10.4103/ijem.ijem_322_22.
[74]	KIM B J, LEE S H, KOH J M. Bone health in adrenal disorders[J]. Endocrinol Metab，2018，33(1)：1-8. DOI：10.3803/EnM.2018.33.1.1.
[75]	KIM B J, KWAK M K, KIM J S, et al. Higher sympathetic activity as a risk factor for skeletal deterioration in pheochromocytoma[J]. Bone，2018，116：1-7. DOI：10.1016/j.bone.2018.06.023.
[76]	YOKOMOTO-UMAKOSHI M, UMAKOSHI H, FUKUMOTO T, et al. Pheochromocytoma and paraganglioma：an emerging cause of secondary osteoporosis[J]. Bone，2020，133：115221. DOI：10.1016/j.bone.2020.115221.
[77]	DUTTA D, NAGENDRA L, CHANDRAN M, et al. Impact of pheochromocytoma or paraganglioma on bone metabolism：a systemic review and meta-analysis[J]. J Clin Densitom，2024，27(3)：101501. DOI：10.1016/j.jocd.2024.101501.
[78]	VAN LOON K, ZHANG L, KEISER J, et al. Bone metastases and skeletal-related events from neuroendocrine tumors[J]. Endocr Connect，2015，4(1)：9-17. DOI：10.1530/EC-14-0119.
[79]	TISCHLER A S, POWERS J F, PIGNATELLO M, et al. Vitamin D₃-induced proliferative lesions in the rat adrenal medulla[J]. Toxicol Sci，1999，51(1)：9-18. DOI：10.1093/toxsci/51.1.9.
[80]	TIRABASSI G, SALVIO G, ALTIERI B, et al. Adrenal disorders：is there any role for vitamin D?[J]. Rev Endocr Metab Disord，2017，18(3)：355-362. DOI：10.1007/s11154-016-9391-y.
[81]	MALTONI C, MINARDI F, PINTO C, et al. Results of three life-span experimental carcinogenicity and anticarcinogenicity studies on tamoxifen in rats[J]. Ann N Y Acad Sci，1997，837：469-512. DOI：10.1111/j.1749-6632.1997.tb56895.x.
[82]	BOLANOWSKI M, HALUPCZOK J, JAWIARCZYK-PRZYBYŁOWSKA A. Pituitary disorders and osteoporosis[J]. Int J Endocrinol，2015，2015：206853. DOI：10.1155/2015/206853.
[83]	SCHLECHTE J, WALKNER L, KATHOL M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia[J]. J Clin Endocrinol Metab，1992，75(3)：698-703. DOI：10.1210/jcem.75.3.1517357.
[84]	YUN S J, SANG H, PARK S Y, et al. Effect of hyperprolactinemia on bone metabolism：focusing on osteopenia/osteoporosis[J]. Int J Mol Sci，2024，25(3)：1474. DOI：10.3390/ijms25031474.
[85]	UYGUR M M, FRARA S, DI FILIPPO L, et al. New tools for bone health assessment in secreting pituitary adenomas[J]. Trends Endocrinol Metab，2023，34(4)：231-242. DOI：10.1016/j.tem.2023.01.006.
[86]	MAZZIOTTI G, CHIAVISTELLI S, GIUSTINA A. Pituitary diseases and bone[J]. Endocrinol Metab Clin North Am，2015，44(1)：171-180. DOI：10.1016/j.ecl.2014.10.014.
[87]	BARNABAS R, GAUDA B S, CHERIAN K E, et al. An uncommon cause of osteoporosis[J]. J Family Med Prim Care，2018，7(2)：455-457. DOI：10.4103/jfmpc.jfmpc_350_17.
[88]	SAMPERI I, LITHGOW K, KARAVITAKI N. Hyperprolactinaemia[J]. J Clin Med，2019，8(12)：E2203. DOI：10.3390/jcm8122203.
[89]	BIOLETTO F, BERTON A M, BARALE M, et al. Skeletal fragility in pituitary disease：how can we predict fracture risk?[J]. Pituitary，2024，27(6)：789-801. DOI：10.1007/s11102-024-01447-3.
[90]	WANG L, CHEN K, DUAN L, et al. Bone microarchitecture impairment in prolactinoma patients assessed by HR-pQCT[J]. Osteoporos Int，2022，33(7)：1535-1544. DOI：10.1007/s00198-021-06289-4.
[91]	ANDEREGGEN L, FREY J, ANDRES R H, et al. Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas[J]. Sci Rep，2021，11(1)：5122. DOI：10.1038/s41598-021-84606-x.
[92]	DANDINOĞLU T, AKARSU S, TEKIN L, et al. A 22-year-old man with severe osteoporosis due to prolactinoma[J]. J Clin Rheumatol，2013，19(6)：341-343. DOI：10.1097/RHU.0b013e31829ce57c.
[93]	ROLLA M, JAWIARCZYK-PRZYBYŁOWSKA A, HALUPCZOK-ŻYŁA J, et al. Complications and comorbidities of acromegaly-retrospective study in Polish center[J]. Front Endocrinol，2021，12：642131. DOI：10.3389/fendo.2021.642131.
[94]	GIUSTINA A, BARKAN A, BECKERS A, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities：an update[J]. J Clin Endocrinol Metab，2020，105(4)：dgz096. DOI：10.1210/clinem/dgz096.
[95]	WYDRA A, STELMACHOWSKA-BANAŚ M, CZAJKA-ORANIEC I. Skeletal complications in acromegaly[J]. Reumatologia，2023，61(4)：248-255. DOI：10.5114/reum/169918.
[96]	SHI S M, ZHANG L, YU Y R, et al. Acromegaly and non-parathyroid hormone-dependent hypercalcemia：a case report and literature review[J]. BMC Endocr Disord，2021，21(1)：90. DOI：10.1186/s12902-021-00756-z.
[97]	JAWIARCZYK-PRZYBYŁOWSKA A, HALUPCZOK-ŻYŁA J, SYRYCKA J, et al. Trabecular bone score and osteoprotegerin as useful tools in the assessment of bone deterioration in acromegaly[J]. Front Endocrinol，2022，13：862845. DOI：10.3389/fendo.2022.862845.
[98]	ROSENDAL C, ARLIEN-SØBORG M C, NIELSEN E H, et al. Changes in acromegaly comorbidities，treatment，and outcome over three decades：a nationwide cohort study[J]. Front Endocrinol，2024，15：1380436. DOI：10.3389/fendo.2024.1380436.
[99]	MAZZIOTTI G, BATTISTA C, MAFFEZZONI F, et al. Treatment of acromegalic osteopathy in real-life clinical practice：the BAAC（bone active drugs in acromegaly）study[J]. J Clin Endocrinol Metab，2020，105(9)：e3285-3292. DOI：10.1210/clinem/dgaa363.

内分泌代谢系统疾病与继发性骨质疏松症的研究新进展

Progress in the Research of Endocrine and Metabolic System Diseases and Secondary Osteoporosis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 99

相关文章 15

编辑推荐

Metrics

留言

[1]	谭文彬, 李佳, 刘明玉, 路永欣, 程雅欣. 神经系统疾病及相关治疗药物对骨质疏松症影响的研究进展[J]. 中国全科医学, 2025, 28(17): 2092-2100.
[2]	曹沁涵, 卓肖, 夏雨菡, 车杨曦, 陈敏. 2024年V1/V2版《NCCN直肠癌临床实践指南》更新要点解读[J]. 中国全科医学, 2025, 28(17): 2070-2074.
[3]	贺婷, 李佳, 谭文彬. 循环系统疾病与继发性骨质疏松症的研究新进展[J]. 中国全科医学, 2025, 28(17): 2101-2112.
[4]	李佳, 谭文彬. 继发性骨质疏松症防治困境与对策探究[J]. 中国全科医学, 2025, 28(17): 2075-2081.
[5]	顾洁, 黄延焱. 罕见病诊治及全过程管理：全科医生的作用不可或缺[J]. 中国全科医学, 2025, 28(16): 1955-1960.
[6]	隋鸿平, 李婷婷, 姜桐桐, 夏云龙, 史铁英. 血管内皮生长因子信号通路抑制剂相关高血压的血压管理研究进展[J]. 中国全科医学, 2025, 28(15): 1932-1936.
[7]	邓毅凡, 何胜虎, 张晶, 朱莉. 钠-葡萄糖共转运蛋白2抑制剂对急性心肌梗死患者经皮冠状动脉介入治疗术后主要不良心血管事件发生的影响：一项Meta分析[J]. 中国全科医学, 2025, 28(15): 1884-1890.
[8]	孙沁瑜, 邓毅凡, 何胜虎, 张晶. 中性粒细胞/淋巴细胞比值、单核细胞/高密度脂蛋白胆固醇比值及两者联合对急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术后造影剂肾病的预测价值研究[J]. 中国全科医学, 2025, 28(15): 1891-1897.
[9]	曹干, 邓毅凡, 何胜虎, 张晶. 乳酸脱氢酶与白蛋白比值与急性ST段抬高型心肌梗死急诊经皮冠状动脉介入治疗术后患者预后的相关性研究[J]. 中国全科医学, 2025, 28(15): 1878-1883.
[10]	宋洪娜, 许洪梅, 刘玉环, 王青龙, 汤云昭, 于翔. 冠心病合并糖尿病患者经皮冠状动脉介入治疗术后共病随访模式的构建及应用效果研究[J]. 中国全科医学, 2025, 28(14): 1737-1743.
[11]	朱胜杰, 刁华琼, 杭晓屹, 孙文军. 不同中成药注射液治疗后循环缺血性眩晕效果的网状Meta分析[J]. 中国全科医学, 2025, 28(14): 1795-1808.
[12]	夏雨菡, 卓肖, 曹沁涵, 廖星雨, 罗国樑, 唐太春, 陈敏. 2024年V4版《NCCN结肠癌临床实践指南》更新解读[J]. 中国全科医学, 2025, 28(14): 1689-1693.
[13]	马桂芬, 章倩, 孙菁. 2024年《NCCN胃癌临床实践指南》更新要点解读[J]. 中国全科医学, 2025, 28(14): 1681-1688.
[14]	刘彩萍, 张艳华, 汤剑平, 汪程鹏, 薛丰丰, 王慧娟, 李传威, 张广亚, 李华芳. 注射用利培酮微球（Ⅱ）在精神分裂症患者维持治疗中的疗效和安全性研究[J]. 中国全科医学, 2025, 28(13): 1622-1627.
[15]	王德祥, 原佳雯, 陆沁云, 杭宇豪, 鲁俊, 程璐. 清肺化瘀通腑方治疗时机对脓毒症相关急性呼吸窘迫综合征治疗效果及预后的影响研究[J]. 中国全科医学, 2025, 28(12): 1500-1505.